Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Arcus Biosciences (RCUS – Research Report) and Palvella Therapeutics (PVLA – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioMarin Pharmaceutical (BMRN)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical. The company’s shares closed last Monday at $62.92, close to its 52-week low of $60.63.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $86.20, which is a 34.5% upside from current levels. In a report issued on February 12, Jefferies also maintained a Buy rating on the stock with a $113.00 price target.
See the top stocks recommended by analysts >>
Arcus Biosciences (RCUS)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Arcus Biosciences. The company’s shares closed last Monday at $18.85, close to its 52-week high of $19.11.
According to TipRanks.com, Goonewardene is a 1-star analyst with an average return of
Currently, the analyst consensus on Arcus Biosciences is a Moderate Buy with an average price target of $28.83, a 50.0% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $44.00 price target.
Palvella Therapeutics (PVLA)
Truist Financial analyst Danielle Brill maintained a Buy rating on Palvella Therapeutics today. The company’s shares closed last Monday at $87.84.
According to TipRanks.com, Brill is a 4-star analyst with an average return of
Currently, the analyst consensus on Palvella Therapeutics is a Strong Buy with an average price target of $184.19, implying an 116.2% upside from current levels. In a report issued on February 9, H.C. Wainwright also maintained a Buy rating on the stock with a $200.00 price target.
